ACET Adicet Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $99.13M | $99.32M |
| SG&A expense | $22.99M | $28.29M |
| Operating income | -$122.11M | -$127.61M |
| Interest expense | $36,000 | $4,000 |
| Pretax income | -$116.80M | -$117.12M |
| Income tax | $0 | $0 |
| Net income | -$116.80M | -$117.12M |
| EBITDA | -$115.73M | -$121.15M |
| EPS (basic) | -16.95 | -21.33 |
| EPS (diluted) | -16.95 | -21.33 |
| Weighted avg. shares (diluted) | 6.89M | 5.49M |
| Balance sheet | ||
| Cash & equivalents | $38.92M | $59.40M |
| Current assets | $160.93M | $180.14M |
| PP&E, net | $16.53M | $22.52M |
| Total assets | $192.35M | $220.22M |
| Current liabilities | $21.53M | $19.39M |
| Total liabilities | $33.15M | $33.61M |
| Shareholders' equity | $159.21M | $186.61M |
| Shares outstanding | 9.59M | 5.16M |
| Cash flow statement | ||
| Operating cash flow | -$95.25M | -$92.38M |
| Capital expenditure | $1.74M | $1.12M |
| Free cash flow | -$96.98M | -$93.50M |
| Investing cash flow | $2.39M | -$119.24M |
| Financing cash flow | $75.25M | $111.31M |
| Depreciation & amortization | $6.38M | $6.47M |
| Stock-based compensation | $14.27M | $22.23M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.